Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145799 | 0.85 | KMT2A (0.53) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL10477884 | 0.85 | KMT2A (0.53) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL5852441 | 0.85 | LMNA (0.59) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8481818 | 0.83 | LMNA (0.58) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6190389 | 0.83 | LMNA (0.58) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8482579 | 0.83 | LMNA (0.58) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8715559 | 0.83 | F2 (0.49) | HIF1AMAOBTAAR1HTR3ATSHR | |
| SCHEMBL9878279 | 0.83 | MAOB (0.61) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL11074823 | 0.83 | MAOB (0.61) | LMNAHIF1ACYP1A2PTGS1SLC6A2 | |
| SCHEMBL15499831 | 0.83 | LMNA (0.61) | LMNAHIF1ACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| EP-0650368-A1 | USE OF CALPAIN INHIBITORS IN THE INHIBITION AND TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH INCREASED CALPAIN ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994000095-A2 | USE OF CALPAIN INHIBITORS IN THE INHIBITION AND TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH INCREASED CALPAIN ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0236624-B1 | SUBSTITUTED PHENYL ETHANOL AMINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1993-08-11 | — | — | EP | disclosed |
| US-5153210-A | Hypoglycemic agent, animal growth regulator; veterinary medicine | BEECHAM GROUP P.L.C. (GB) | 1992-10-06 | — | — | US | disclosed |
| EP-0236624-A2 | Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-09-16 | — | — | EP | disclosed |
| EP-0171702-A1 | Benzoxazinone derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
| US-4460580-A | N-Alkylated aminoalcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0005848-B1 | N-ALKYLATED AMINOALCOHOLS AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | disclosed |
| EP-0005848-A1 | N-Alkylated aminoalcohols and their salts, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-12-12 | — | — | EP | disclosed |
| US-4146638-A | CARDIOTONIC, VASODILATION, HYPOTENSIVE, ANTIARRYTHMIA AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | LMNA 3153/4885HIF1A 1750/4885CYP1A2 2665/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | LMNA 3084/4885HIF1A 2490/4885CYP1A2 2859/4885 |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | LMNA 3153/4885HIF1A 1750/4885CYP1A2 2665/4885 |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | GID4, RNF5, UBE3C | LMNA 3292/4885HIF1A 1886/4885CYP1A2 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.